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There is currently sufficient evidence available indicating that dengue and chikungunya 
viruses might be one of the causes of fever in Tanzania. Lately, the dengue outbreak in Dar es 
Salaam-Tanzania has raised concerns over the spread and distribution of these arboviruses 
with respect to human movements. The present study was conducted to screen for and 
chikungunya virus (CHIKV) dengue virus (DENV) from febrile patients in Morogoro 
Municipality which had no reports of outbreaks during an inter-epidemic period with high 
risk of transmission. Three hundred and twelve febrile individuals presenting to the outpatient 
department on selected health centers were tested for viral RNA to evaluate the circulation of 
DENV and CHIKV during March-May 2018. DENV and CHIKV detection in sera samples 
was performed using multiplex real-time reverse transcription polymerase chain reaction 
(RT-PCR). Chikungunya virus was detected in four out of 312 screened serum samples 
indicating acute cases while no DENV was identified. Chikungunya virus was among the 
causes of acute undifferentiated fever among febrile patients in Morogoro municipality with a 
lower prevalence of 1.3% highly prevailing amongst female aged 20-49 years. No acute cases 
among patients under 10 years of age were detected. The result provides insight into presence 
of potentially active circulation of CHIKV among febrile patients seeking medical attention, 
in Morogoro Municipality, Tanzania. Improvement of CHIKV case detection and reporting at 
the point of care routine laboratory investigations is critical in reducing misdiagnosis of 
mosquito-borne viral infection. Monitoring of arboviral activities in human populations, as 
well as mosquitoes, should be performed in order to avoid maintenance of CHIKV that may 
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1.1 Background of the problem 
Dengue virus (DENV) and chikungunya virus (CHIKV) infections are among the major 
global impact mosquito-borne viral diseases in several malaria endemic regions worldwide 
(WHO, 2013). According to WHO (2017), about 2.5 billion individuals (40% of the 
worldwide populace) are considered in danger of dengue transmission, while 50 million 
instances of the contamination are unsurprising to happen every year universally. In contrary, 
chikungunya infection has a very low death rate about (<0.1%) in hospitalized cases although 
individuals may experience long term effects, such as Chronic inflammatory rheumatism, that 
can last up to years after contradicting the infection (Bloch, 2016).  Data on the event and 
predominance of dengue in Africa is constrained in spite of the way that flare-ups have been 
research center affirmed. Moreover, the total global burden of these viruses is uncertain, since 
symptoms and signs are very similar to other febrile illnesses and actual cases are 
underreported or misclassified (Bhatt et al., 2012; Norrby, 2014; WHO, 2012).  
There is a reported evidence of DENV and CHIKV circulating in Tanzania mainland (Ward 
et al., 2017) and Zanzibar (Grazia et al., 2012). It is suggested that Dengue is very much 
circulating in coastal regions, including Dar es Salaam and Zanzibar (Vairo et al., 2016), 
while Chikungunya is highly prevalent on the northern zone (Faustine et al., 2017; Hertz et 
al., 2012; Kajeguka et al., 2016). The Dengue outbreak of 2014 in Dar es Salaam was the 
undeviating proof of DENV transmission in Tanzania, reported to spread to seven regions of 
Tanzania territory, including Morogoro region (Mboera et al., 2016; Mweya et al., 2016). 
Significant levels of precipitation and temperature reasonable for DENV and CHIKV 
transmissions, as well as presence of primary vector Aedes aegypti mosquito being endemic 
in much of Tanzania, accounts for a shred of strong indirect indication for the existence of 
endemic arboviral transmission in the area (Ward et al., 2017). Factors like uncontrolled and 
rapid urbanization which expands the urban population, poverty, ineffective public health 
infrastructure, increased international travel, and inadequate sewage systems which often 
leads to breeding sites for Aedes and habitually favors the spread of endemic dengue and 
chikungunya transmission in Tanzania (Neiderud, 2015).  
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It is reported that, the proportion of febrile cases due to other apart from malaria has recently 
increased in Sub-Saharan Africa (D’Acremont et al., 2014). Studies done recently in 
Tanzania has shown that, victims affected with acute dengue infection are every likely 
misdiagnosed and regularly given plausible diagnoses of Malaria, UTI and  also pneumonia 
(Chipwaza et al., 2014; Ward et al., 2017). A diminished degree of dengue and chikungunya 
responsiveness amongst health attendants and absence of differential pathogen diagnosis in 
determining febrile fever causes in dengue-endemic locales accounts for dengue 
underreporting and misclassification (Reyburn, 2004; WHO, 2009). These patients are often 
treated with anti-malaria or antibiotic drugs (Hertz et al., 2012), which are largely ineffective 
against dengue. The implication of misdiagnosis and underreporting of diseases of such may 
result in decline in economy (Hume et al., 2008), increase of drug-resistant malaria strains as 
the result of over-prescription of antimalarial drugs (Wongsrichanalai et al., 2007), and 
increased risk of morbidity and death rates (Oladosu & Oyibo, 2013).  
Early accurate arbovirus diagnosis is important in detecting viral RNA in human serum or 
plasma during an intense stage of infection for disease surveillance and implementation of 
control responses (Lai et al., 2007). Reliability of arbovirus detection rely on infection stage 
and type of sample used, in which serology and molecular detection are the most common 
tests used (Korrapati et al., 2015). Serology techniques were considered unsuitable for virus 
surveillance in the present study as the technique gives seroprevalence frequency of 
individuals with evidence of prior infection, on top of the reported cross-reactivity of anti-
dengue antibodies between flaviviruses (Paula, 2004). The IgM assay can be detected 3-5 
days and can persist for 2 weeks post onset of illness, making it unsuitable in detecting acute 
infection (Kim et al., 2015). Virus detection by PCR offers the advantage of being able to 
detect virus during an severe stage of the infection since the virus persists in the infected host 
up-to 14 days after infection (Kong et al., 2006). Additionally, PCR technique can provide 
insight to the circulating serotype essential for virus surveillance. Therefore, in the current 
study the concurrent status of DENV and CHIKV infections was comprehended on a high 
risk region during an inter-epidemic period. 
1.2 Statement of the problem  
A number of chikungunya and dengue outbreaks have been reported including the recent 
dengue outbreak in parts of Dar es Salaam (neighboring region) in 2018. Other studies have 
reported the existence of arboviruses in vector mosquitoes, highly suggesting the underlying 
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circulation of arboviruses in Tanzania. Most arboviral studies in Tanzania have been 
conducted during epidemic periods and little is known about the virus circulation during the 
inter-epidemic period while more attention is given to the highly endemic regions leaving the 
non-foci regions at high risk of transmission. Currently, no virus surveillance study has been 
done to screen for dengue and chikungunya viruses as one of the underlying causes of fever 
among febrile patients visiting health centers in Morogoro municipality. Finding from this 
study will assist in updating data on the present status of dengue and chikungunya infections 
in Morogoro municipality after an outbreak four years ago in Kilosa District and on the 
recent outbreak in the city Dar es Salaam that kept this study area at the risk of transmission. 
Screening of febrile patients across different demographic characteristics may assist in a 
specific focus for public health prevention and control measures in impacting febrile illnesses 
in Tanzania. 
1.3 Rationale of the Study 
Finding from this study will assist in updating data on the present status of dengue and 
chikungunya infections in Morogoro municipality after an outbreak four years ago in Kilosa 
District and on the recent outbreak in the city Dar es Salaam that kept this study area at the 
risk of transmission. Screening of febrile patients across different demographic characteristics 
may assist in a specific focus for public health prevention and control measures in impacting 
febrile illnesses in Tanzania. 
1.4 Objectives 
1.4.1 General objective 
To determine prevalence and distribution of Dengue and Chikungunya infections and the 
associated socio-demographic characteristics in Morogoro Municipality. 
1.4.2 Specific objectives 
(i) To screen for Dengue and Chikungunya viruses among febrile patients in the study 
area. 
(ii) To determine social-demographic characteristics associated with the distribution of 




1.5 Research questions 
(i) What is the present molecular epidemiology status of DENV and CHIKV infections 
among the selected population in Morogoro Municipality as regards to previous 
DENV outbreak in Kilosa district and the recent outbreak in Dar-es-Salaam? 
(ii) What are the socio-demographic characteristics associated with the distribution of 
DENV and CHIKV infections during the inter-epidemic period in Morogoro 
Municipality? 
1.6 Significance of the study 
Yields of this investigation will aid better understanding of the concurrent status of dengue 
and chikungunya viral surveillance in Morogoro region. Evidence of the concurrent status of 
DENV and CHIKV infections by molecular screening among the selected population in 
Morogoro municipality as regards to the previous outbreak in Kilosa, Morogoro and the 
recent outbreak in Dar-es-Salaam. This may assist clinicians in making considerable 
decisions when consulted with patients with symptoms that pose a diagnostic dilemma hence 
help in the proper prescription of medicines. Timely public health reports and investigations 
on disease status prior epidemics and risks of transmission may aid in attracting and avoid 
vanishing of significant investors and stakeholders as well as substantially improving the 
national economy. Scrutinizing affected individuals by both age and gender may provide 
stratified prevalence data of DENV and CHIKV infections that may assist in targeting 
specific preventive measures. 
1.7 Delineation of the study  
The study was a cross-sectional hospital based study which was conducted to screen for 
dengue DENV and CHIKV in sera from (312) patients with fever and malaria-like symptoms 
on selected health centres in Morogoro municipality (n = 5) during March-May 2018. 
Prevalence of these viruses was determined by using Multiplex real-time reverse 
transcription-polymerase chain reaction. And the distribution of CHIKV and DENV during 
the inter-epidemic period in Morogoro municipality was analyzed from the social-







2.1 Dengue virus infection 
2.1.1 Dengue fever 
It has been anticipated that 500 000 people influenced with serious dengue call for 
hospitalization every one year  and nearly 2.5% of those affected with dengue fever die 
(WHO, 2012). Dengue is the furthermost quickly spreading mosquito-borne viral disease in 
the world, and it has expanded 30-fold in the past 50 years and in the current decade because 
of geographical extension to different nations from urban to rural settings (WHO, 2014). 
Every one of the four DENV serotypes have been separated in Africa, with DENV2 reported 
to be associated with most outbreaks (Amarasinghe et al., 2011; Were, 2012). 
Dengue fever may be categorized clinically as (a) Probable dengue, (b) Dengue which has 
cautioning signs and (c) Severe dengue (WHO, 2012). The disease manifestation has three 
stages: febrile, critical, and convalescence or recovery. The period of incubation only lasts for 
about 4-10, followed by the febrile stage, which lasts for about 2-7 days causing unspecified 
signs and symptoms. These includes high grade fever (38.8-40.5 ֯C), pain on the front head, 
retro-ocular pain (pain behind the eyes), malaise, maculopapular rash, arthralgia, myalgia, 
nausea, vomiting. It is at this phase that the diseases is clinically tough to differentiate it from 
other fever-like diseases and the assessment whether the disease is in extreme or non-serious 
form is difficult. In the febrile phase, the total blood count in the earliest abnormality is a 
gradual decrease in the all-out number of leucocytes in the body. This should raise concern 
that the victim has signs and symptoms of dengue. On the other hand, critical phase lasts for 
about 24-48 hours and it occurs when the fever diminishes and followed by bleeding and a 
raise in capillary permeability (Epelboin et al., 2012; WHO, 2016).  
The final results in plasma leakage clinically demonstrated as pleural effusion and ascites 
together with increased hematocrit levels, leukopenia with neutropenia, decreased platelet 
count, and lymphocytosis with 15-20% atypical shapes. These resemble to dengue shock 
syndrome or severe dengue as when plasma levels decreases, there is high risk of an 
individual getting shock. If shock prolongs, progressive organ deterioration may occur 
resulting into death. Promisingly, if patient survives the critical phase there is steady 
restoration of body fluids, general well-being improves and hemodynamic status stabilizes 
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within 48-72 hours. There is an increase in total white blood cell count, neutrophils and 
decreased lymphocytes. The increased platelet count subsequently increases leucocytes. This 
parallels to the recovery stage (Beltrán-Silva et al., 2016; Rückert et al., 2017). Generally, 
indications and signs of dengue infection may be very similar to Chikungunya infection and 
other febrile illnesses (WHO, 2009).  
2.1.2 Virus structure and survival  
The (+)ssRNA enveloped virus that causes Dengue comprises of four serotypes (DENV-1, 
DENV-2, DENV-3, and DENV-4), which belong to the family Flaviviridae and genus 
Flavivirus (Taslim et al., 2018). All four serotypes circulate in similar ecological niche and 
they affect closely identical syndromes in humans although they are antigenically dissimilar 
(Guzman et al., 2010). Infection with only one serotype gives only limited immunity against 
other serotypes but a permanent immunity to that strain (Lupi, 2011). Dengue virus structure 
is almost spherical in structure, with a width of approximately 50 nm. The virus core is the 
nucleocapsid, a structure that is made of the viral genome along with C proteins. This 
nucleocapsid is surrounded by a viral envelope, which is a lipid bilayer that is derived from 
the host. Embedded in the viral envelope are 180 copies of the E and M proteins that span 
throughout the lipid bilayer. These proteins form a protective outer layer that controls virus 
entry into human cells (Lopez & Arias, 2010). 
The viral genome is a single strand of RNA. It is referred to as positive-strand RNA because 
it can be directly translated into proteins. This viral genome encodes ten genes (Coffey et al., 
2013). The viral genome is translated as a single, long polypeptide and then cut into ten 
encoded proteins. The genome encodes three structural (capsid [C], membrane [M], and 
envelope [E]) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) 
proteins that are involved in viral replication and assembly (Jhan et al., 2017). The NS1 
protein amongst these structural proteins interacts with the host immune system and thereby 
evoking T cell responses. This attained response has been used as a diagnostic marker in 
detecting dengue fever infection (Erickson et al., 2010; Mukhopadhyay et al., 2005). 
The infection replication process starts when the infection joins to a human skin cell. The 
skin cell's membrane then encloses around the virus forming a pouch (endosome) which 
covers around the virus particle. The dengue virus is able to enter a host cell using the normal 
cell process of nourishment by engulfing large particles from outside (Lopez & Arias, 2010). 
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The virus then joins with the endosomal membrane once it is inside the cell and it is released 
into the cytoplasm in which the virus particles releases the viral genome. Viral RNA is then 
translated into a single polypeptide that is cut into ten proteins, followed by replication of the 
viral genome. The latter is the virus assembly process which occurs on endoplasmic 
reticulum (ER) surface in which the structural proteins and recently synthesized RNA are 
released out from the ER (Navarro-Sanchez et al., 2003). The immature viral particles are 
then conveyed via the trans-Golgi network where they develop and transform to their 
infectious state. On the final stage, matured viruses are then released out from the cell and 
can ready to go to infect other cells (Mukhopadhyay et al., 2005).  
2.1.3 Vector organism 
Dengue and chikungunya viruses are spread via a human-to-mosquito-to-human cycle of 
transmission (Fig. 1). Infections spread by a vector necessitates that a vector organism should 
be able to get a pathogen, maintain it and effectively transmit it to a susceptible host. 
Temperature, accessibility of vertebrate hosts and vector population density accounts for 
external factors necessary for vector-borne infection, whereas mosquito survival and virus 
replication abilities count for internal factors (Coffey et al., 2013). The internal physiology 
and innate behavioral traits of the vector, its ability to transmit an agent along with feeding 
duration and host preferences are the important intrinsic factors that the viral pathogen use to 
overcome obstacles before diffusion to another host (Agarwal et al., 2014).  
 
Figure 1: Mosquito-borne virus infection and transmission process (Coffey et al., 2014) 
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The mosquito species Aedes aegypti  and, to a lesser magnitude,  Aedes albopictus  are the 
prime vectors in dengue and chikungunya viruses (Fig. 2) in sub-Saharan Africa, although 
these viruses are also retained in in sylvatic cycles including primates and forest dwelling 
Aedes species in some parts of Africa (Hertz et al., 2012).  
 
Figure 2: Mosquito vectors for DENV transmission (Rodhain and Rosen, 1997) 
Aedes aegypti is a small, dark mosquito identified by the shinning white bands on its legs and 
a silver-white pattern of scales on the body. It dwells in tropical and subtropical regions 
across the world, primarily in latitudes ranging from 35°N to 35°S.  Temperatures within 
5°C-40°C are essential for mosquito survival although they are incapable of surviving cold 
winters since Aedes aegypti needs a warm climate, these mosquitoes cannot live at elevatons 
above 1000m where the temperature is cooler. Aedes aegypti feeds mainly on human blood 
during daytime and it thrives in close contiguity to humans where they spend their whole 
lives in and around the houses and incubate eggs (Brady et al., 2014; Erickson et al., 2010). It 
is an impatient mosquito as the minor movement interrupts its feeding process, and therefore 
in a short interval of time several people may be bitten for one blood meal. Aedes aegypti 
takes more than one blood meal before laying eggs that is during a gonotrophic cycle, unlike 
most mosquitoes (Gibbons & Vaughn, 2002). Adult mosquitoes feeding frequency increases 
as the temperature increases about 18°C with a reduced humidity. High mosquito densities 
are usually expected during and after a rainy times of a year, this is highly attributed by high 
precipitation, rainfall accumulation, intensity and frequency. Moreover, the presence of 




2.1.4 Dengue virus transmission 
After a mosquito has fed on the dengue virus infected blood, it becomes a dengue vector. 
During the viremic period when the sullied individual has raised degrees of the dengue 
disease in the blood it is at that point that the mosquito takes the infection during its blood 
supper. The virus then spreads all the way through the mosquito's body for about 8-12 days. 
Subsequently at this interval of time, the affected mosquito can then re-infect dengue virus to 
a new individual upon a mosquito bite during feeding. After getting dengue infection, the 
mosquito remains infected with DENV for the rest of its life about 3-4 week period that is 
why the infected mosquitoes continues spreading the virus to healthy individuals in their 
entire life spans period (Hume et al., 2008; Lupi, 2011; Rückert et al., 2017). 
Female mosquitoes feeds on humans as they require blood for eggs production. During their 
lifetime, each and every female mosquito lay various lots of eggs, and regularly Aedes 
aegypti take a considerable amount of blood dinners before laying a group of eggs. An 
affected female mosquito carries the dengue virus in its salivary glands (Cao-Lormeau, 2009; 
Sim et al., 2012). During feeding, a diseased female mosquito infects the host with the 
dengue virus by inoculating its saliva into the human host so as to avoid blood clotting to the 
host and to facilitate the feeding process. The greater part of dengue diseases are transmitted 
by mosquito bite in spite of uncommon occasions in which a contaminated expecting mother 
can transmit the infection to the embryo and during organ transplantations or blood 
transfusions from tainted contributors (Friedman et al., 2014). 
The eggs of Aedes aegypti mosquitoes can survive dry environments for quite a lot of 
months. Eggs laid in a dry container can allow development of new mosquitoes only when 
the container is filled with water (Hanley et al., 2008; Kuno et al., 1997). Because of this 
adaptation elimination of mosquito populations has become difficult. Globally, dengue 
outbreaks occur annually during the rainy season, the time at which mosquito breeding 
conditions are conducible. In highly populated regions dengue fever poses a particular health 
threat as epidemics are more likely to occur on zones with an enormous number of people 
interacting with a high numbers of mosquito vectors than in more secluded and remote areas 
such as in the mountains (WHO, 2009).  
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2.1.5 Virulence mechanisms 
Dengue infection contaminate juvenile dendritic cells in the skin by means of the vague 
receptor dendritic cell-explicit ICAM3-getting non-integrin (DC-SIGN). The tainted dendritic 
cells at that point develop and move to local or local lymph nodes to proceed to introduce 
viral antigens to T cells and along these lines starting cell and humoral immune reactions. 
The virus multiplies and then enters the bloodstream. The infection replication likewise 
happens in macrophages in lymph nodes, liver parenchymal cells, spleen alongside in fringe 
blood monocytes. Antibody-dependent enhancement (ADE) is performed by both vitro and in 
vivo, macrophages. This happens when safe edifices that structure between dengue infections 
and non-killing antibodies contaminates mononuclear phagocytes through their Fc receptors. 
Virus uptake by macrophage cells proliferates and may result into a disease severity forms 
including dengue shock syndrome (Brady et al., 2014; Erickson et al., 2010; Navarro-
Sanchez et al., 2003).  
Upon obtaining dengue antibodies either by maternal or natural forms against one serotype 
prevention against infection with another dengue serotype is not guaranteed. Past exposure of 
the disease to one serotype could expand the disease triggered by exposure to a second strain 
as the four distinct serotypes do not cross-neutralize but cross-react. On re-infection with the 
disease, the body then reacts to the first strain with which it was infected while putting up a 
solid immune response (Stephan et al., 2002). An elevated level of DENV in the blood 
(viremia) is then observed four days after an affected Aedes aegypti mosquito bite, this 
complaint persists for about five to twelve days. An individual displays no indications of 
dengue fever on day one of viremic phase then five days later an individual develops dengue 
fever symptoms that lasts about a week or more. 
2.2 Chikungunya virus infection 
Chikungunya fever is caused by the Alphavirus of the family Togaviridae (WHO, 2017) and 
comprises of three different strains: the East, Central and South African strain (ECSAS), 
West African strain, and Asian strain (Pongsiri et al., 2012). Alphaviruses are enveloped 
single-stranded positive-sense RNA genome with a spherical virion 60 to 70 nm in diameter 
(Schmaljohn & McClain, 1996). The genome is about 11.7 kb long and comprises of two 
regions, a non-structural domain (Fig. 3) which encodes four viral non-structural proteins 
(nsP1- nsP4), essential for replication, polyprotein processing and the structural domain. The 
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non-structural proteins also synthesize the 26S sub-genomic mRNA which ultimately 
produces five individual structural proteins which consist of the viral capsid (C), two 
envelope glycoproteins (E1 and E2), and two peptides (E3 and 6K) (Hernandez et al., 2014). 
  
Figure 3: Alphavirus genome organization (Hernandez et al., 2014) 
Chikungunya virus may cause acute, subacute, and chronic infections. Upon biting by an 
infected mosquito an individual usually develops signs and symptoms of the disease 3–7days 
after the bite. Acute chikungunya fever typically lasts for 3–10 days and is regarded as a 
sudden onset of high fever that takes up to a week and severe joint pain which is commonly 
observed in the hands and feet but can manifest to other joints. This fever (39–40°C) is 
mostly accompanied by irregular shaking chills (Fig. 4). Other signs and symptoms include 
diffuse back pain, headache, rash, myalgia with back and shoulder pain, nausea, vomiting, 
conjunctivitis and slight photophobia may occur.  
Most patients develop maculopapular rash 2–5 days after fever onset. On the other hand, joint 
pain and swelling can be severe enough to affect the individual’s ability to walk (Johnson et 
al., 2008; Tilak et al., 2016). Individuals with chronic Chikungunya infection usually 
improves after the ten first days of symptoms onset, whereas these symptoms can reoccur 2–3 
months after the initial infection. This usually involves exacerbation of pain in previous 
injured joints and bones, distal polyarthritis and tenosynovitis in wrists and ankles (ADHS, 
2016). In most cases the viremia is present during the first 48 hours of illness, although in 
some patients this may carry on for up to 4 days. Most patients recover completely within a 
few weeks although up to 10% of individuals experience chronic joint pain, swelling and 




Figure 4: Chikungunya case classification algorithm (ADHS, 2016) 
2.3 Dengue and chikungunya virus screening  
Monitoring arboviral incidence and prevalence with time is crucial so as to avoid unexpected 
rise in the proportion of severe cases as the procedure measures the disease background rate 
which will alert and promote investigation, intervention and prevention measures. Prompt 
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warning of a disease epidemic alerts clinicians on the necessity of diagnosis and properly 
treat DENV and CHIKV cases while enabling health services in allocating human and 
material resources more efficiently and to healthier engaging the community on prevention 
and control measures, and consecutively reducing disease transmission and refining clinical 
practices (WHO, 2012; ADHS, 2016). Dengue plagues diminishes the beneficial limit and 
financial development of numerous segments of society because of their quick extension and 
delayed spans (WHO, 2009). For instance, certain groups of people require special attention 
as they depend on others who take care of them and together with the immediate 
surroundings (e.g. older people who stays alone, travelers, children in daycare programmes, 
migrant workers and soldiers). These individuals if not accurately screened may also pose 
high risk of dengue virus transmission to health care locations. 
Early anticipation is the best measure in dengue and chikungunya avoidance and control 
since currently no vaccine is available. The current dengue and chikungunya prevention 
strategies are reactive rather than anticipatory as they are every so often implemented late 
thereby reducing the chances for preventing transmission and subsequent controlling the 
epidemic (Viennet et al., 2016; WHO, 2009). These reactive strategies results into short-term 
behavioral change as individuals may fail to uphold government efforts in partnership with 
personal and community responsibility for dengue and chikungunya preventions and control 
(Reich et al., 2016). 
Most outbreaks brings about the uncertainty, misperception and a sense of urgency. Public 
risk communication during outbreaks has a core task of announcing the epidemic timely 
while giving precise and transparent information on what measures people can do to prevent 
themselves from getting the disease. This helps in building public trust in which subsequently 
permits them to respond to the dangers of transmission with even added rational and logical 
reactions. Additionally, media involvement prior a rise in number of cases enhances the 
chance in raising public awareness of the disease while fostering community and individual 
mitigations against spread of the disease (Parks et al., 2004; WHO, 2005). 
2.3.1 Status of dengue infection 
The study on epidemiology of dengue: past, present and future prospects by Murray et al. 
(2013) revealed that globally, dengue fever is the furthermost critical mosquito-borne viral 
illness because of its wide distribution of the virus and its vectors throughout tropical and 
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subtropical regions. This geographic spreading out has been favored with prompt increases in 
epidemics and incident cases resulting in the more severe forms of dengue.  
The current data available to ascertain the global true impact of dengue most likely 
underestimates the economic and social burden of the disease since there is insufficient 
disease surveillance data, underreporting and misdiagnosis cases (Murray et al., 2013). 
Dengue is anticipated to increase due to aspects like the current changing aspects of 
environmental change, travel, exchange, globalization, settlement and viral movement.  
The presence of other prevalent febrile diseases such as Malaria, poor surveillance system, 
low level of attentiveness among health care practitioners and lack of differential diagnosis 
capacity to rule out dengue accounts for the misdiagnosis and underreporting of dengue in 
Africa (Amarasinghe et al., 2011). The clinical presentation of DENV infections is 
challenging as it is similar to other various causes of febrile illnesses such as malaria (Gubler, 
1998). It  is important to report the raising threat of DENV fever as no specific therapy or 
vaccine is available upto date therefore early detection of epidemic cases and accurate 
clinical management may assist in reducing mortality cases of dengue (Sim et al., 2012). 
Another preventive measure is the effective control of the vector organism. Amended 
reporting of dengue cases and disease surveillance are crucial to comprehend the true global 
impact (WHO, 2012). Increasingly exact information will illuminate the prioritization of 
wellbeing approach, inquire about, and monetary resources toward controlling the disease 
(Murray et al., 2013). 
2.3.2 Prevalence of dengue in Morogoro Region 
Causes and dynamics of dengue may be addressed by the environmental and climatic 
situations on the respective area throughout the relevant period. The role of indigenous 
temperature variation, rainfall timing and magnitude of the rain episodes observed in April 
2018 was insufficient to engage in a precarious role on the spread of Dar-es-Salaam outbreak 
to Morogoro Region.  
The decreased convenience of breeding spots in flower pots, car tires and plastic containers 
as it was elaborated in an entomology study of Mboera et al. (2016), following community 
education for malaria prevention strategies may have reduced the impact of vector breeding, 
thereby limiting virus survival. In the rural areas of Kilosa and Kilombero districts, it was 
previously observed that majority of water containers around the houses were sheltering A. 
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aegypti larvae whereas in the same surroundings, buckets, clay vessels, tins, and loading 
water drums were the most collective breeding sites (Mathias et al., 2017). Transmission of 
dengue infection depend on the productivity rate of female Aedes mosquitoes from breed 
dwellings which eventually defines the quantity of adult mosquitoes.  
The extension of topographical dispersion of A. aegypti and potential risks to spreading 
dengue virus is highly facilitated with the changing climatic condition. Temperature 
influences on the extrinsic incubation duration, adult transience and water developmental 
rates of the vector (Butterworth et al., 2017; Kraemer et al., 2015). Temperatures on cold 
autumn weather during the rainy season early on 2018 may have caused a decrease in the 
quantity of adult mosquitoes dropping below the critical threshold in which the incubation 
period is diminutive than the typical mosquito lifespan. This may have effectively reduced 
vector capacity and reduced viral transmission, resulting in a significant reduction in dengue 
cases in Dar-es-Salaam and subsequently banned further spread of the disease. 
To avoid the unpredicted rise in cases of DENV and CHIKV upon an outbreak, it is 
important for the government to monitor arboviral incidence and prevalence with time 
(Fritzell et al., 2018) as most arboviral preventive approaches are highly implemented late 
instead of defensive (Tambo et al., 2017). Such approaches result into a flood use of 
resources during outbreaks, temporary behavioral changes in which at worse individuals may 
fail to cooperate with the government efforts in prevention schemes and tackling outbreaks 
(WHO, 2009). Screening and surveillance records are of public health and economic 
importance at the National level (Nsubuga et al., 2006) so as to protect investors’ interests. 
Production of surveillance data which are highly underreported and the capability to convert 
these records into usable information is vital to applicable public health action (Groseclose & 
Buckeridge, 2017). 
2.4 Molecular detection of DENV and CHIKV 
2.4.1 Multiplex real-time RT-PCR 
For viruses with an RNA genome such as DENV and CHIKV, reverse transcription (RT) is 
combined with Polymerase Chain Reaction (PCR) in making RNA into a complementary 
DNA (cDNA) since RNA cannot directly serve as a PCR template. Reverse transcriptase 
enzyme is an RNA dependent DNA polymerase that can synthesize a DNA strand from RNA 
template (Viljoen et al., 2005). According to Korrapati et al. (2015), several real time RT-
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PCR methods exploiting different combinations of primers, probes and fluorescents in 
detecting, serotyping, and quantification of DENV and CHIKV have been described. Hemi-
nested RT-PCR which was initially developed in 1992 and improved to date is one of the 
PCR currently in use. The assay involves two cycles of amplification followed by gel 
electrophoresis process in detecting amplicons. Challenge involved is that these tests require 
about a day or more to accomplish significantly resulting in a limitation of the clinical utility 
of the assay and a high risk of contamination (Waggoner et al., 2013). 
2.4.2 AccuPower® ZIKV (DENV, CHIKV) Multiplex Real-Time RT-PCR 
The Bioneer’s Dual Hot start technology has established a high specific and sensitive 
AccuPower® ZIKV (DENV, CHIKV) Multiplex Real-Time RT-PCR Kit for detecting viral 
RNA in clinical samples. Dual- Hot Start™ excludes non-specific complementary DNA and 
non-specific DNA amplifications so as to allow the currently available most sensitive one-
step RT-PCR assays. This kit is intended to enhance reproducibility and fasten usage by 
vacuum-drying the entire PCR reagents together with primers, probes, dNTPs, DNA 
polymerases, and salts. The primer-probe set demonstrates efficiency at maximum value in 
amplification by the use of bioinformatics algorithms which matched to the AccuPower® 
diagnostic kits. 
The AccuPower® ZIKV (DENV, CHIKV) Multiplex Real-Time RT-PCR Kit is a diagnostic 
kit intended for the qualitative detection of Zika, Dengue and, Chikungunya Virus RNA in 
human samples including plasma and serum through real-time (RT-PCR) (WHO, 2016). The 
system comprises of an ExiPrep device used for an automatic nucleic acid preparation and an 
Exicycler for detection and amplification of nucleic acid. Real-time PCR selectively 
amplifies the target sequence while monitoring the amplification progress in real-time 
through a fluorescent dye. The amount of ZIKV, DENV and CHIKV in target sequence 
available to each amplification cycle is relatively direct to the generated signal from the 
fluorescent labeled oligonucleotide probes which is bound to the amplified target. Specific 
primers together with hydrolysis probe brings about the specificity of the assay. Labelling of 
the hydrolysis probe (5’-Fluorescent reporter; 3’- Quencher) with a corresponding pair of 




MATERIALS AND METHODS 
3.1 Material, reagents or tools used in this study 
The equipment, reagents and materials used in this study are indicated in Appendix 1. 
3.2 Study area 
The investigation was conducted in Morogoro Municipality in Morogoro region, Tanzania. 
The district occupies a total of 260 square kilometers of land covered with a population of 
about 315 866 (URT, 2013). Morogoro Region occupies about 8.2% of the entire area of 
mainland Tanzania. The climate of the region can be described as a bimodal rainfall dispersal 
characterized by two rainfall peaks annually, associated with a dry season to separate the 
short rains (October–December) from the long rains (March-May). The cool-dry season 
records a temperature as low as 12℃ averagely, while a temperature of 38℃ is observed 
during the hot-dry seasons.   
Sampling was conducted in Mazimbu, Mafiga, Sabasaba, Nunge and SUA health centers 
(Fig. 5) in Morogoro municipality, Morogoro region. The municipality has a moderately 
dense human population with tertiary institutions and industries which attracts many people 
from all walks of life thus several characteristics of the area favors Aedes mosquito breeding 
and transmission of arboviral diseases. Nunge is a business area characterized by a high 
number of traders. Mazimb u has vegetation cover with high-populated neighborhoods and 
inadequate sewage systems which often leads to breeding sites for Aedes. Located in this 
ward is the busiest bus terminal in which affected vectors are likely to be transported along 
with human movement from the epidemic region of Dar es Salaam. Mafiga is a highly 
populated area with middle-class individuals. The area is characterized by vegetation. 
Sokoine University of Agriculture (SUA) hospital is where located and are surrounded by 
rural at the at the fringe of the Uluguru Mountain, described by low human populace however 




Figure 5: Map of Morogoro municipality indicating the five Health centers of this study 
(indicated by orange color) 
3.3 Study design 
This was a cross-sectional hospital-based study that was conducted from March-May 2018 
among individuals presenting to the outpatient department with febrile condition (fever ≥ 
37.5 °C) in five Health centers in Morogoro municipality. 
3.4 Study population 
The study participants were febrile individuals presented at the selected health facilities in 
Morogoro municipality, Morogoro region.  
3.4.1 Sample size determination 
The desired sample size was derived by the formula n=Z2PQ/d2. Where n is the sample size; 
P is the expected prevalence in the target population, Q is 1-P; Z is 1.96; standard error, d is 
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the level of statistical significance (0.05). Prevalence value of 20.9% was used representing 
maximum uncertainty (Vairo et al., 2016). Hence, the estimated minimum sample size was 
255 with an added 10% samples for data inconsistencies, giving a total sample size of 293.  
3.4.2 Inclusion criteria 
The inclusion criteria for enrolling individuals into this study were, Presentation with fever ≥ 
37.5 °C, malaria-like symptoms and patient agreeing to consent. 
3.4.3 Exclusion criteria 
The exclusion criteria used for this study were individuals with chronic and debilitating 
illnesses. 
3.5 Sampling technique 
Individuals who met the above criteria were successively enrolled based on the attendance 
ratio at each of the health centers until the desired sample size was attained. Samples were 
obtained from 5 health centers in Morogoro Municipality: SUA Hospital, Nunge Health 
center, Mafiga Health center, Sabasaba Health center and Mazimbu Hospital. The health 
facilities were selected on the basis of providing primary and advanced healthcare services 
and possessing sufficient laboratory facilities for routine diagnostics.  
3.5.1 Blood sample collection 
Samples from peripheral venous blood (up to 4 ml) were drawn into plain or EDTA 
anticoagulant tubes at the time of enrollment as per attached SOP. Each plain and EDTA tube 
was labeled with patient name, age, sex and the date the sample was taken. All samples were 
collected and centrifuged on site to obtain serum/plasma and furthermore aliquoted into cryo-
vials (2 ml each) and later transported in cold chain to NIMR-Morogoro laboratory analysis. 
At the laboratory, these samples were barcoded and stored in freezers at -20 °C in 




Figure 6: Blood serum samples all set for RNA extraction 
3.6 Laboratory work 
3.6.1 RNA extraction and RT-PCR 
Stored serum/plasma was collected and subjected to an in vitro automated diagnostic system 
a one-step multiplex RT-PCR by using AccuPower® RT-PCR kit (Bioneer, Seoul, Republic 
of South Korea) following manufacturer’s instructions and with some few modifications. The 
premix contained specific primers and probe for chikungunya and dengue RNA viruses. It 
comprised of a strip of eight tubes with all components required for cDNA synthesis and 
PCR, including M-MLV RT, thermostable DNA polymerase, RNAse inhibitor, and deoxy-
ribonucleotide triphosphates (Fig. 7). Enzyme viability is preserved for a long period even 






Figure 7: ZIK-1111 PCR premix (96 reactions) consisting of PC, IPC, NTC and the 
Optical sealing film 
The RT-PCR was carried out in accordance to the kit company’s instructions as per the 
following preparations. The premix enclosed optimum concentrations of the entire essential 
components needed for complementary DNA synthesis and amplification in one tube of 0.2 
ml. Every single premix tube contained a stabilizer and was well-preserved in a lyophilized 
system. The primer mixture was arranged through mixing conserved forward and reverse 
primer 400 nM and 200 nM respectively with DEPC-treated distilled water.  
The lyophilized content was then dissolved, vortexed and then briefly spinned. Briefly, 400 
µL of NTC (Non-template control) was added into both PC (positive control) and NC 
(negative control) sample loading tubes, 7 µL of PC were added into the PC sample loading 
tubes and 400 µL of blood serum were then added to the remaining sample loading tubes, the 
quantity used ensured that a maximum amount of serum was available for virus detection and 
subsequently reducing contamination risks from duplicating runs. Furthermore, 14 blood 
serum sample loading tubes, 1NTC loading tube and 1PC loading tubes (A total of 16 loading 
tubes) were placed in one ExiPrep for RNA extraction. A 30 minutes RT-PCR step was 
performed at 50 °C followed by a 15 min Taq polymerase activation at 95 °C, 40 cycles of 
PCR denaturation at 95°C for 30 s, 60 °C of annealing for 30 s and 72 °C extension for one 
minute. The RT-PCR was conducted in a Master cycler gradient machine (Eppendorf, 




Figure 8: Automated Multiplex real-time RT-PCR workflow Bioneer, 2017 (WHO, 
2016) 
The use of AccuPower RT-PCR premix highly facilitated the diagnosis work as each solo 
tube contained all the necessary parts for the RT-PCR premix and only fewer steps are 
needed in the process. This helped to reduce the time required to prepare the assays and 





Figure 9: Laboratory activities involving preparing serum sample to be loaded in the 
ExiPrep 
3.7 Data analysis 
Data collected in this study were recorded and analyzed using Microsoft Office-Excel 2016 
(Microsoft, California, USA) for cleaning and descriptive statistics. The demographic 
backgrounds including, age, sex and locality were analyzed. Multiplex real-time RT-PCR 
data analysis was done by calculating the threshold cycle (CT) value represented the positive 
amplification of the gene in RT cycle numeral. 
3.8 Ethical considerations 
Ethical approval to perform the study was obtained from the Medical Research Coordinating 
Committee (MRCC) of the National Institute of Medical Research 
(NIMR/HQ/R.8a/Vol.IX/1896) and go-ahead to perform the study in the health facilities was 
pursued from the Morogoro Region Health Authority. Participants were requested to affirm 
in participating in the study through the informed consent form and participants who did not 
contribute in the study received normal routine care according to their condition and 
presentations. All data collected was further coded for confidentiality purposes as well as 






RESULTS AND DISCUSSION 
4.1 Results 
4.1.1 Study participants characteristics 
During the sample collection period, from March to May 2018, the study enrolled 312 febrile 
individuals from the five selected health centers in Morogoro municipality. 
The majority of enrollments were from Mazimbu Hospital (42%) followed by Nunge (21%), 
Mafiga (14%), Sabasaba (12%) and SUA (12%) health centers. The majority of patients 
enrolled (40%) were adults aged (20-29) years of the study participants, (74%) were females 
and (26%) were males. The exact number of participants and percentages is as summarized in 
Table 6 below: 
Table 1: Social demographic characteristics of study participants (N = 312) 
Variables Frequency Percentage 
Hospital 
Mazimbu Hospital 







Nunge Health Centre 64 21 







Age in years   
≤ 9 17 6 
10-19 48 15 
20-29 125 40 
30-39 60 19 




Sex   
Male 82 26 
Female 230 74 
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4.1.2 Screening for DENV and CHIKV by RT-PCR 
Three hundred and twelve (312) serum/plasma samples were detected for DENV and CHIKV 
using AccuPower® ZIKV (DENV, CHIKV) Multiplex Real-Time –PCR (Fig. 10 & 11), 
results summarized in Table 7. Chikungunya and Dengue cases were categorized in 
accordance to the World Health Organization (2009) criteria and confirmed acute 
chikungunya was well-defined as a positive PCR result. Among all febrile participants, only 
4 cases with a prevalence of (1.28%) met the WHO criteria for CHIKV confirmed cases (Fig. 
12). None of the cases were positive for dengue by Multiplex Real-Time RT-PCR. 













Nunge Health Centre 0 1 







Age in years   
0-9 0 0 
10-19 0 0 
20-29 0 2 
30-39 0 1 




Sex   
Male 0 0 
Female 0 4 
 
The results from the amplification plot of tested samples representing (1) CHIKV positive 






Figure 10: The amplification plot of Multiplex Real-time RT-PCR showing the CHIKV 
positive sample, the IPC and negative CHIKV and DENV samples 
4.2 Discussion 
Monitoring arbovirus infections as part of virological surveillance in humans including virus 
isolation from human serum and mosquito inoculations has greatly influenced outbreak 
predictions globally (Gubler, 1998). It has been previously reported that DENV and CHIKV 
are amongst the viral causes of fever in patients on the lookout for health care in Morogoro 
region (Chipwaza et al., 2014). 
The study has demonstrated a prevalence of CHIKV infection (1.28%) in 312 febrile victims 
seeking medical care in health facilities during the inter-epidemic period. Because of poor 
accessibility to diagnostic capabilities in areas with malaria epidemics, most febrile cases  
have been previously and recently treated as cases of malaria (D’Acremont et al., 2014; 
Kinimi et al., 2018a; Mishra et al., 2011; WHO, 2009).This is attributed by the similar 
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clinical manifestations of indications and signs in the early stages of dengue, chikungunya 
and other febrile illnesses. The diagnostic capacity to rule-out chikungunya, dengue and other 
infections has remained an obstacle to their control and prevention in resource-limited 
settings (Mardekian & Roberts, 2015). 
This study has revealed about 1.3% of CHIKV prevalence, suggesting very minimal active 
CHIKV transmission in Morogoro Municipal. This prevalence is less than the previously 
reported chikungunya prevalence in different regions of the country (Chipwaza et al., 2014; 
Faustine et al., 2017; Kajeguka et al., 2016; Kinimi et al., 2018b). The variation in many 
studies may be endorsed by the seasonal variations, climatic changes, timing of blood 
sampling in an acute infection, and type of test used for virus detection (Hertz et al., 2012). 
Furthermore, CHIKV infection symptoms last for about 2-10 days, the time in which virus is 
circulating in blood and it can be identified by PCR only within this limit. The sensitivity of 
acute infection diagnosis after the viremic phase becomes minimal as virus levels are 
significantly reduced (Kajeguka et al., 2016).  
Age and sex are proxy features termed as the explicit behavior that cause higher exposure to 
mosquito bites (Bisimwa et al., 2016; Furuya-Kanamori et al., 2016). In this study, molecular 
detection of CHIKV was significantly lower in children than in adults, which may indicate 
current virus exposure. Most adults aged between 18 and 55 years practices a lifestyle of 
staying outdoors during dusk and dawn hours which favors Aedes mosquito bites. 
Consequently, such exposure to mosquito propensity makes them vulnerable to mosquito-
borne diseases as well as dengue and chikungunya (Dhimal et al., 2015; Kinimi et al., 2018). 
Moreover, employed individuals and livestock keepers who are associated with daily 
movements from home to work have an increased chance of contracting Aedes mosquito bites 
at early morning and at dusk from different locations (Camara et al., 2018).  
In this study, chikungunya cases were exclusively present in adult’s female ranging from 20-
49 years of age. Similarly,  other studies reported adulthoods as a potential risk factor to 
DENV and CHIKV infections (Mardekian & Roberts, 2015; Ndosi et al., 2016). Cultural 
dynamics in Tanzania where females are mostly responsible for farming, housekeeping, 
cooking, fetching water and fire woods, together with other risk factors such as reduced body 
immunity in lactating and pregnant mothers may influence female individuals to mosquito-
borne exposure. In contrary, these findings differ from a study conducted in Magugu district 
in the Northern zone (Faustine et al ., 2017), which reported that male sex had five times 
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higher odds of being CHIKV positive. This may be attributed by a different lifestyle 
practiced between people of two different locations as most of individuals in the North-east 
zone are pastoralists in which men are highly involved than women. 
Our findings may suggest the possibility of affected Aedes mosquitoes that minimally 
circulate CHIKV active cases in Morogoro Municipality. It has been ascertained by the 
unpublished study conducted by Ahedor (2016) that there is a relatively high abundance of 
Aedes aegypti mosquitoes in Morogoro region. Suitable weather and climate conditions are 
essential for the persistence, distribution, and transmission of pathogens, hosts and vectors for 
the disease. Fluctuations in weather conditions may pose an influence on communicable 
diseases by affecting the pathogens, hosts, vectors, and the earth (Wu et al., 2014). Many 
arboviral infectious diseases are extremely subtle to climatic and weather fluctuations (Tian 
et al., 2015). The low prevalence of CHIKV may also be attributed by the possible fact that, 
may be the CHIKV was minimally present in blood when the samples were collected for this 
study, hence a sero-prevalence study should have indicated possible presence of CHIKV 
antibodies during the sample collection period, just as it was for serological evidence of 
presence of DENV infection in Morogoro (Chipwaza et al., 2014). 
This study has shown that there were no DENV cases at the selected health centers despite 
the recent outbreak in Dar es Salaam region and its serological evidence in Morogoro 
(Chipwaza et al., 2014). Most of chikungunya and dengue studies which were reported in 
Tanzania were conducted during outbreaks, and they used serological tests and solitary, but 
only a few reported virological prevalence of these arboviruses (Bisimwa et al., 2016; 
Faustine et al., 2017; Kajeguka et al., 2016). Sampling procedure was conducted within a 
short time in March up to May 2018 during the inter-epidemic period. This was the period in 
which a dengue outbreak had occurred in Dar es Salaam city, chances of human movements 
between the two regions could have facilitated spread of the virus, but this did not happen to 
large extent.  
Similarly, another findings conducted in Tanga and Hai in North Tanzania reported no 
prevalence of acute DENV (Hertz et al., 2012). Other study conducted in Morogoro 
municipality to assess the viral infectivity in the vector population by molecular detection 
method reported no DENV was detected (unpublished data) (Ahedor, 2016). Nevertheless the 
results in this study are likely similar with a study performed by Faustine et al. (2017) which 
reported a less dengue virus prevalence of 1 (0.8%) in Magugu district in Northern Tanzania.  
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In contrary, the results from the inter-epidemic study differed from other epidemic findings in 
Tanzania. In 2014, Dengue fever outbreak occurred in Dar es Salaam with more than 400 
confirmed cases and at least three died (Mboera et al., 2016). Additionally, the recent 
outbreak in Dar es Salaam in March 2018 reported 11 confirmed cases (as reported from the 
Ministry of Health). Thus, the samples tested were not detected with DENV but there was a 
probability of affected individuals who did not seek medical attention during this study 
frame. Additionally, dengue patients undergo dehydration upon severe diarrhea and as 
dengue is mostly misdiagnosed in most dengue-endemic areas, these patients tend to recover 
easily after receiving oral rehydration solutions and sufficient resting.  
Limitations in this study were the fact that only a single diagnostic technique was used. This 
kit targeted virus RNA on current infections thereby omitting the chances of finding out past 
exposure to the viruses through serology tests. Moreover, virus detection on vector organisms 
was not involved. The study focused more on screening for these arboviruses which is highly 





CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion 
This investigation was performed on selected health centers in Morogoro municipality to 
screen for DENV and CHIKV from febrile patients during the inter-epidemic period using 
multiplex real-time RT-PCR. Result from this study provides insight into presence of 
minimally active circulation of chikungunya virus (1.3% prevalence) among febrile patients 
seeking medical attention, which may be transmitted in Morogoro Municipality, Tanzania. 
The findings show that CHIKV may also be important cause of fever among febrile patients 
in Morogoro municipality during dengue inter-epidemic period, with a low prevalence. Only 
4 cases of acute chikungunya among 312 studied samples were exclusively prevailing 
amongst female patients aged between 20 and 49 years. The present study findings may show 
the significance of reporting age and gender stratified data as factors (variables) to consider in 
chikungunya surveillance, to help in targeting specific preventive measures. There was no 
detection of DENV at this sampling period, the time in which high risk of transmission of 
dengue epidemics in the neighboring Dar es Salaam was likely to occur. 
5.2 Recommendations 
The present study recommends the following:  
(i) The ministry of health should integrate reliable and affordable arboviral screening 
and diagnostic tests at the point of care routine laboratory investigations to facilitate 
early and accurate diagnosis and management of chikungunya patients and reduce 
misdiagnosis of mosquito-borne viral infections.  
(ii) Clinicians ought to think about chikungunya case discovery when given patients 
having febrile ailment and fever of obscure beginning in order to advance patient 
supervision and add to a progressively vivacious appraisal of infection trouble in 
Tanzania.  
(iii) PCR based diagnosis of both CHIKV and DENV should be carried out together with 
serological tests to avail their possible past infection (sero prevalence), which may be 
overlooked by absence of active CHIKV and DENV in collected blood. This may 
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possibly be the reason for observed low prevalence of CHIKV (1.3%) and zero 
prevalence of DENV herein. 
(iv) The government should initiate regular surveillance programmes in monitoring 
arboviral activities and febrile illness viruses in human populations, as well as 
mosquito vectors and embark an integrated vector control programme at the 
municipal and National level in order to avoid maintenance of the viruses in 
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Appendix 1: Materials and Reagents used in the study 
‐ Vacutainer tubes and needle ‐ Permanent marker pen/ pencil 
‐ Vacutainer holders 
 
‐ Staining jar/ holder 
‐ Cotton wool ‐ Tube rack 
‐ Pipettes ‐ Appropriate PPE 
‐ 70% Ethanol -Xylene cleaning solution 
‐ 
Bionner 
Bioneer kits   -Two‐ply adsorbent tissue 
 
Bioneer kits and instruments used in this study  
Cat no. Kit name Instrument Tests 
Bioneer kits 
ZIK-1111 AccuPower® ZIKV (DENV, 
CHIKV) Multiplex Real-Time 
RT-PCR Kit 
Exicycler™ 96 96 
K-4473 ExiPrep™ Dx Viral RNA Kit ExiPrep™ 16 Dx Fully 




A-2060 Exicycler™ 96 Real-Time 
Quantitative Thermal Block 
Exicycler™ 96 Real-Time 
Quantitative Thermal Block 
96 
A-5050 ExiPrep™ 16 Dx Fully 
Automated Nucleic Acid 
Extraction System 
ExiPrep™ 16 Dx Fully 
Automated Nucleic Acid 
Extraction System 
16 
A-5150 ExiPrep™ 48 Dx ExiPrep™ 48 Dx 48 
A-7040 ExiSpin™ ExiSpin™ 32 
 
 
Contents of the Viral RNA kit (K-4473) for use with BIONEER’s ExiStation™ System 
Reagents Units 
Buffer Cartridge 1 and 2 1 pack each 
Disposable filter tips 3 packs 
Elution tube 1 pack 
Contamination shield filter paper 1 pack 
Protection cover 4 packs 
Waste tray 1 pack 





Contents of the Multiplex Real-Time RT-PCR kit (ZIK-1111) for use with BIONEER’s 
ExiStation™ System 
Reagents Unit Quantity (96 test kit) 
ZIKV Premix 1 Aluminum Foil Bag 8 tubes x 12 strips (96 tubes) 
 
Positive Control RNA 
15 µl / tube 
(Natural 8-tube strip) 
 
8 tubes x 2 strips (16 tubes) 
IPC RNA (Internal Positive 
Control) 
15 µl / tube 
(Yellow 8-tube strip) 
 
8 tubes x 2 strips (16 tubes) 
DEPC-DW (No Template 
Control) 
15 µl / tube 
(Purple 8-tube strip) 
 
8 tubes x 2 strips (16 tubes) 
DEPC-DW 1800 µl / tube 4 tubes 
SL Buffer 1800 µl / tube 8 tubes 
Optical Sealing Film - 1sheet 
Quick Manual - 1sheet 
 
Materials required but not provided by ZIK-1111 Kit. 
Material   Product name/description 
Real-Time PCR instrumentation required for kit 
ZIK-1111 
BIONEER’s 
ExiStation™ Universal Molecular Diagnostic      System 
(Cat. No. A-2200): (Integrated platform of Real-Time 
PCR instrument (Exicycler™ 96) and nucleic acid 
extraction Instrument (ExiPrep™ 16 Dx)) 
Exicycler™ 96 Real-Time Quantitative Thermal Block 
(Cat. No. A-2060) Reagent requirements for kit 
ZIK-1111 
ExiPrep™ 16 Dx (Cat. No. A-5050) 
ExiPrep™ Dx Viral RNA Kit (Cat. No. K-4473) 
ExiSpin™ (Cat. No. A-7040) 
Materials  requirements for kit 
ZIK-1111 
Disposable powder-free gloves 
Appropriate volume pipette set 
Sterilized pipette tips with filters 
1.5 ml micro tubes or 15 ml conical tubes 





Appendix 2: Informed consent form 
Respondent’s ID and Year ……………………………………. 
Consent to participate in this study  
Greetings! My name is 
…………………………………………………………………… 
(Name of a person administering the questionnaires) 
The purpose of this research is to investigate the etiologies of acute febrile infections in 
Morogoro Region. You are being asked to participate in this study because you have 
particular knowledge and experiences that may be important to the study. 
 
Participation involvement 
If you agree to participate in this study, the following will occur: 
1. You will be interview about previous illness history or your baby and a blood sample 
from your vein or blood from your baby may be collected. 
2. In addition, some personal information will be gathered like your age, height and 
weight level of education, occupation and ethnicity. 
3. Your identity (name) will be stored at a confidential place in the hospital together 
with your medical files, and researchers have only access to a code in which nobody 
will be able to recognize. 
4. In case you are willing to participate in future with further research within this or 
future projects you can specify. 
5. You will be interviewed only once for approximately 10 minutes in a private setting. 
 
Benefits 
There will be no direct benefits to you; however, the information you provide will help to 
increase the understanding on febrile illness. This will help to formulate prevention and 
control strategies aimed at reducing the acute febrile infections. 
 
Confidentiality 
I assure you that all the information collected from you will be confidential. Only the main 
research in the project and your medical doctor will have access to the information. The final 
report will contain responses and laboratory results from several participants without any 
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references to individuals. We will not put your name or others identifying information on the 
records of the information you provide. 
Risks  
You will be interview as described above, in case some questions make you feel 
uncomfortable, you are free not to respond to them. There are no risks associated with the 
collection of blood samples taken from you or your child.  
 
Rights to withdraws and alternatives 
Your participation in the study is on a voluntary basis. If you choose not to participate in the 
study or decide to stop participating in the study there will not be any problem refusal to 
participate or withdraws from the study will not affect the quality of health service you get 
from the hospital. 
 
In case of injury  
We do not anticipate that any harm will occur to you or your baby as a result of participation 
in this study. 
Whom to contact 
If you have questions about this study, you may contact the following: 
Principal Investigator of the research project Dr. Lucas E Matemba NIMR laboratory, P.O 
Box 476, Morogoro. Tel 0757 313 626. 
National Health Ethics review Committee (NATHREC), 2448-Baraka Obama Avenue, and 
P.O Box 9653, Dar es Salaam. 
Certification of consent 
I have been invited to take part in the study of “investigation of Acute Febrile Infections in 
Morogoro region, Tanzania” I have read the foregoing information or it has been read to me 
and I have understood I agree to participate in this study. 
 
Signature  
Name of the participating mother (in capital letter) …………………………………………. 
 




Signature of witness (if a participant cannot read)……………………………………………. 
 
Signature of research assistant ………………………………………………………………… 
 
Date consent  
Signed ……………………………......Are you willing to be in contact for future research?      
YES  
         
 NO 
Address P.O Box ……………………………………………………………………………. 
Hamlet ……………………… Village………………………… Ward ……………….……… 













Appendix 3: Laboratory protocol for AccuPower® ZIKV (DENV, CHIKV) 
Multiplex Real-Time RT-PCR Kit 
 
ExiStation™ Procedure 
The device is able to perform Nucleic acid extraction from 48 samples within an hour with a 
combination of 3 ExiPrep™ 16 Dx and 1 Exicycler™ 96. It has enhanced usability with 
automated processes such as decapping and capping of sample tubes and a built-in automatic 
cartridge puncher. 
Preparation; 
1) Turn on the computer pre-installed with ExiStation™ Manager Software. 
2) Execute the ExiStation™ Manager Software by clicking the icon located on the 
desktop. 
3) Turn on the ExiPrep™16 Dx (A-5050) by pressing the main power button located at 
the front of the instrument. Press the ‘STARTING’ image displayed on the LCD to 
initiate instrument startup. 
4) Press the ‘MISC SET’ button on the LCD screen (or the ‘Load’ button on the 
software). Attach the filter paper onto the Contamination Shield. Attach the 
prepared Contamination Shield then the Tip Protector in the instrument. Press the 
‘Misc Set’ button again. 
5) The ExiStation™ Manager Software has six distinct parts. Prep - control nucleic 
acid extraction (ExiPrep™16 Dx instrument). Assign PCR - transfer sample 
information from ‘Prep’ to ‘PCR’ (Exicycler™ 96) and assign for PCR run. The 
result after the PCR run present experiment information and sample result 
information 
6) Click the ‘Prep’ tab on the upper left of the main screen to initiate the nucleic acid 
extraction process. 
7) Click the pull-down arrow for ‘Diagnosis Kit 1’. A popup will appear. 
8) Inspect the Buffer Cartridge and mark the used well by clicking on the corresponding 
location to exclude the used well from sample assignment. Select ‘OK’ to finish. 
9) The program will automatically allocate the NTC and PC wells. The default setting 
is one (1) for each of NTC and PC. 
10) Input each lot number of the diagnostic kit and the prep kit. Click the ‘Sample ID’ 




11) Check that all necessary materials and accessories are present before proceeding. 
12) Clean the surface (preferably a positive pressure BSC) where work will be 
performed. 
13) Remove the shrink-wrap enclosing both Buffer Cartridges and then remove the 
acryl lids in a positive pressure BSC. 
14) Punch the film with the Hole Punch according to the layout mapped on the software. 
15) Cover Buffer Cartridges and with the acryl lids after film punching is complete. Take 
the necessary number of strips of the Diagnostic Kit Tubes from the freezer. Remove 
the foil covering the tubes. Insert appropriate numbers of Diagnostic Kit Tubes into 
the Elution Tube Rack. 
Sample Loading 
1) Clean the negative pressure Biosafety Cabinet (BSC) on which the nucleic 
acid extraction preparation will be performed. Clean the surface with 70% 
Ethanol or 5% nitric acid solution before and after use in order to prevent 
contamination. After each use, turn on the UV lamp to eliminate 
contaminants. 
2) Add 400 ㎕ of Sample Loading (SL) Buffer, 1x PBS or normal saline into 
pretreated samples and completely dissociate the cell pellet using a pipette. 
3) Take out the necessary number of Sample Loading Tubes from the 
magazine and insert them into rack holes. 
4) Take the original clinical sample containers or Sample Loading (SL) buffer (for 
NTC and PC) and pipette into the Sample Loading Tubes by following steps 5) 
through 8). 
5) For the tube that is assigned as control (NTC and PC), add 400 ㎕ Sample 
Loading (SL) buffer. (supplied with the AccuPower®  Diagnostic Kit) 
6) Additionally, add 5 ㎕ of PC only into the appropriate PC wells.  (supplied  with  the 
AccuPower® Diagnostic Kit) 
7) Move the filled Sample Tube into the Sample Tube Rack. 
8) Uncap the original clinical sample container and pipette 400 ㎕ of sample into the 
next available Sample Loading Tube. Move the Sample Loading Tube into Sample 
Tube Rack after pipetting each sample. 
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9)  Repeat step 8) until all samples are loaded. 
10) Take the Sample Tube Rack and load onto the Setup Tray. 
11) Place the Waste Tray onto the Setup Tray. Slide the base plate in and close the door 
of the ExiPrep™16 Dx. 
12) Click the ‘RUN (▶)’ button of the ExiStation™ Manager Software. Double check 
whether all accessories for the extraction are loaded properly according to the 
‘Check ExiPrep Setting’ list and check the boxes. Click the ‘OK’ button to initiate 
the prep process. Nucleic acid extraction process takes between 80 minutes and 100 
minutes depending on the type of nucleic acid. 
 
PCR Preparation 
1) Click ‘Assign PCR’ tab and check the box of each ‘Prep Work List’ to assign 
PCR position. Checked ‘Prep Work List’ is assigned to the PCR position 
corresponding to the prep instrument 1 to 3 in order. 
2) After the nucleic acid extraction process is finished, the cooling block is 
automatically turned off. Select the ‘Prep’ tab again and click “Store ON” on the 
control panel to turn the cooling block on for long-term storage. 
3) Open the door of the ExiPrep™16 Dx (A-5050) after the nucleic acid extraction 
process is complete, and then remove the Elution Tube Rack. 
4) Remove Protection Cover according to Protection Cover Separation Tool utility 
method. 
5) Seal PCR Tube using Optical sealing film and proceed to the next step. 
6) Taking care not to flip the orientation of the tubes, Place the Elution Tube Rack 
on the PCR Preparation Plate with the corresponding ExiPrep™16 Dx number. 
7) Seal the Diagnostic Tubes with the adhesive Optical Sealing Film. 
8) Right before the PCR reaction, completely mix the tube contents using 
ExiSpin™ (A-7040) for 2500rpm for 5 sec. Hard vortex for 20 sec. / 20 cycles 
9) While the ExiSpin™ is operating, you can start the Exicycler™ 96. 
10) Turn the Standby Power Switch, located at the rear of the instrument ON. The 
front ring-LED status light should turn on RED. 
11) Press the front Operation Power Switch for 3 seconds. A brief self-test sequence 




12) Push the Door Switch for 2 seconds to slide the 96-well thermal block out. Insert 
the reaction tubes in their pre-determined locations. After sample loading is 
complete, push the Door Switch for 2 seconds to close the door. 
13) Place the mixed premix tubes into the assigned well position of Exicycler™ 96 
right after the ExiSpin™ cycling is complete.  
14) Remove all consumables and components, starting with the Buffer Cartridges 
and various racks from the instrument and discard all liquids and consumables 
in their appropriate containers. 
15) Press the ‘Misc Set’ button, remove the Tip Protector and Contamination Shield, 
and then press the ‘Misc Set’ button again. 
16) Push the Base Plate in, shut the instrument door and initiate UV sterilization by 
clicking “UV ON” on the control panel. 
17) Select ‘Assign PCR’ tab and confirm the assigned ‘Prep Work List’. After the 
‘Prep’ process, ‘Current Step’ will be presented as ‘Prep End’ and the upper-
status bar will be changed to ‘Ready to PCR’. Initiate PCR run by clicking the 
activated ‘PCR Start’ button at the bottom right of the window. 
18) A popup will appear prompting the user to enter a Work List Name. Click ‘OK’ 
after entering a name to generate a Work List for Real-Time PCR. 
19) After entering the Work List Name, ‘PCR’ tab will be activated and the 
Exicycler™ 96 will automatically initiate PCR run. 
 
Data Analysis 
After the PCR run is finished, select ‘Result’ tab to check the results of each sample. 
Interpretation of Results 
The test uses 2 wells of each NTC and PC to determine the validity of the 
experiment, and each reaction includes IPC in wells of samples as well as NTC and PC 
to check whether PCR works.  NTC: to determine whether the sample is 
contaminated in the process of sample pretreatment, nucleic acid extraction, and PCR 
preparation (prevent false-positive error) PC: to determine whether target RNA is 
properly amplified (prevent false-negative error) IPC: to check whether PCR is 
inhibited by the sample and to determine the amplification of nucleic acids in each 
well. High concentrations of target DNA can lead to a reduced or absent fluorescence 
signal of IPC due to PCR competition.  
53 
 
The validity of IPC is determined by Ct value of IPC signal. If its Ct value is within 
the specified range, it is valid. If the Ct value is out of the specified range, it is 
invalid. The validity of PC and NTC is determined by the Ct value of the target signal. 
If the assay is valid, target Ct will be ‘undetermined’ in NTC well and PC Ct value will 
be within its specified range.  If the control results are invalid, take measures 
according to User’s Guide 9 troubleshooting. The result of IPC determines the 
validity of the test, and Ct value of the target signal determines whether the target is 
‘Detected’ or ‘Non-detected’. Cut-off value: to classify results as positive or 
negative. The cut-off value is determined to utilize statistical technique, probit 
analysis. The low value of confidence interval (CI) of LoD is converted into Ct value 
derived from the LoD test. The cut-off Ct value determines the target RNA detection 
results as positive with 97.5% probability. 
 
